Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Identifieur interne : 003A05 ( Ncbi/Merge ); précédent : 003A04; suivant : 003A06Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Auteurs : Julianne Bayliss [Australie] ; Lilly Yuen [Australie] ; Gillian Rosenberg [Australie] ; Darren Wong [Australie] ; Margaret Littlejohn [Australie] ; Kathleen Jackson [Australie] ; Anuj Gaggar [États-Unis] ; Kathryn M. Kitrinos [États-Unis] ; G Mani Subramanian [États-Unis] ; Patrick Marcellin [France] ; Maria Buti [Espagne] ; Harry L A. Janssen [Canada] ; Ed Gane [Nouvelle-Zélande] ; Vitina Sozzi [Australie] ; Danni Colledge [Australie] ; Rachel Hammond [Australie] ; Rosalind Edwards [Australie] ; Stephen Locarnini [Australie] ; Alexander Thompson [Australie] ; Peter A. Revill [Australie]Source :
- Gut [ 1468-3288 ] ; 2017.
Descripteurs français
- KwdFr :
- ADN viral (analyse), Adulte, Adulte d'âge moyen, Analyse de séquence d'ADN, Antigènes de surface du virus de l'hépatite B (sang), Antigènes e du virus de l'hépatite virale B (sang), Antiviraux (usage thérapeutique), Charge virale, Femelle, Humains, Hépatite B chronique (sang), Hépatite B chronique (traitement médicamenteux), Hépatite B chronique (virologie), Marqueurs biologiques (sang), Mâle, Méthode en double aveugle, Régions promotrices (génétique), Résultat thérapeutique, Séquençage nucléotidique à haut débit, Séroconversion, Ténofovir (usage thérapeutique), Virus de l'hépatite B (génétique), Virus de l'hépatite B (immunologie).
- MESH :
- analyse : ADN viral.
- génétique : Virus de l'hépatite B.
- immunologie : Virus de l'hépatite B.
- sang : Antigènes de surface du virus de l'hépatite B, Antigènes e du virus de l'hépatite virale B, Hépatite B chronique, Marqueurs biologiques.
- traitement médicamenteux : Hépatite B chronique.
- usage thérapeutique : Antiviraux, Ténofovir.
- virologie : Hépatite B chronique.
- Adulte, Adulte d'âge moyen, Analyse de séquence d'ADN, Charge virale, Femelle, Humains, Mâle, Méthode en double aveugle, Régions promotrices (génétique), Résultat thérapeutique, Séquençage nucléotidique à haut débit, Séroconversion.
English descriptors
- KwdEn :
- Adult, Antiviral Agents (therapeutic use), Biomarkers (blood), DNA, Viral (analysis), Double-Blind Method, Female, Hepatitis B Surface Antigens (blood), Hepatitis B e Antigens (blood), Hepatitis B virus (genetics), Hepatitis B virus (immunology), Hepatitis B, Chronic (blood), Hepatitis B, Chronic (drug therapy), Hepatitis B, Chronic (virology), High-Throughput Nucleotide Sequencing, Humans, Male, Middle Aged, Promoter Regions, Genetic, Sequence Analysis, DNA, Seroconversion, Tenofovir (therapeutic use), Treatment Outcome, Viral Load.
- MESH :
- chemical , analysis : DNA, Viral.
- chemical , blood : Biomarkers, Hepatitis B Surface Antigens, Hepatitis B e Antigens.
- chemical , therapeutic use : Antiviral Agents, Tenofovir.
- blood : Hepatitis B, Chronic.
- drug therapy : Hepatitis B, Chronic.
- genetics : Hepatitis B virus.
- immunology : Hepatitis B virus.
- virology : Hepatitis B, Chronic.
- Adult, Double-Blind Method, Female, High-Throughput Nucleotide Sequencing, Humans, Male, Middle Aged, Promoter Regions, Genetic, Sequence Analysis, DNA, Seroconversion, Treatment Outcome, Viral Load.
Abstract
Hepatitis B e antigen (HBeAg) seroconversion and hepatitis B surface antigen (HBsAg) loss are important clinical outcomes for patients with chronic hepatitis B (CHB) treated with antiviral therapy. To date, there have been few studies that have evaluated viral sequence markers predicting serological response to nucleos(t)ide analogue (NA) treatment.
DOI: 10.1136/gutjnl-2015-309300
PubMed: 27534671
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000224
- to stream PubMed, to step Curation: 000224
- to stream PubMed, to step Checkpoint: 000224
Links to Exploration step
pubmed:27534671Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.</title><author><name sortKey="Bayliss, Julianne" sort="Bayliss, Julianne" uniqKey="Bayliss J" first="Julianne" last="Bayliss">Julianne Bayliss</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Yuen, Lilly" sort="Yuen, Lilly" uniqKey="Yuen L" first="Lilly" last="Yuen">Lilly Yuen</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Rosenberg, Gillian" sort="Rosenberg, Gillian" uniqKey="Rosenberg G" first="Gillian" last="Rosenberg">Gillian Rosenberg</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Wong, Darren" sort="Wong, Darren" uniqKey="Wong D" first="Darren" last="Wong">Darren Wong</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Littlejohn, Margaret" sort="Littlejohn, Margaret" uniqKey="Littlejohn M" first="Margaret" last="Littlejohn">Margaret Littlejohn</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Jackson, Kathleen" sort="Jackson, Kathleen" uniqKey="Jackson K" first="Kathleen" last="Jackson">Kathleen Jackson</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Gaggar, Anuj" sort="Gaggar, Anuj" uniqKey="Gaggar A" first="Anuj" last="Gaggar">Anuj Gaggar</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Foster City, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Kitrinos, Kathryn M" sort="Kitrinos, Kathryn M" uniqKey="Kitrinos K" first="Kathryn M" last="Kitrinos">Kathryn M. Kitrinos</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Foster City, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Subramanian, G Mani" sort="Subramanian, G Mani" uniqKey="Subramanian G" first="G Mani" last="Subramanian">G Mani Subramanian</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Foster City, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Marcellin, Patrick" sort="Marcellin, Patrick" uniqKey="Marcellin P" first="Patrick" last="Marcellin">Patrick Marcellin</name><affiliation wicri:level="1"><nlm:affiliation>Hôpital Beaujon, University of Paris, Clichy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Beaujon, University of Paris, Clichy</wicri:regionArea><wicri:noRegion>Clichy</wicri:noRegion><wicri:noRegion>Clichy</wicri:noRegion></affiliation></author><author><name sortKey="Buti, Maria" sort="Buti, Maria" uniqKey="Buti M" first="Maria" last="Buti">Maria Buti</name><affiliation wicri:level="3"><nlm:affiliation>Liver Unit, Valle d'Hebron (Ciberehd) University Hospital, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Liver Unit, Valle d'Hebron (Ciberehd) University Hospital, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Janssen, Harry L A" sort="Janssen, Harry L A" uniqKey="Janssen H" first="Harry L A" last="Janssen">Harry L A. Janssen</name><affiliation wicri:level="1"><nlm:affiliation>Toronto Center for Liver Diseases, Toronto Western and General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Center for Liver Diseases, Toronto Western and General Hospital, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Gane, Ed" sort="Gane, Ed" uniqKey="Gane E" first="Ed" last="Gane">Ed Gane</name><affiliation wicri:level="1"><nlm:affiliation>New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Sozzi, Vitina" sort="Sozzi, Vitina" uniqKey="Sozzi V" first="Vitina" last="Sozzi">Vitina Sozzi</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Colledge, Danni" sort="Colledge, Danni" uniqKey="Colledge D" first="Danni" last="Colledge">Danni Colledge</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Hammond, Rachel" sort="Hammond, Rachel" uniqKey="Hammond R" first="Rachel" last="Hammond">Rachel Hammond</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Edwards, Rosalind" sort="Edwards, Rosalind" uniqKey="Edwards R" first="Rosalind" last="Edwards">Rosalind Edwards</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Locarnini, Stephen" sort="Locarnini, Stephen" uniqKey="Locarnini S" first="Stephen" last="Locarnini">Stephen Locarnini</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Thompson, Alexander" sort="Thompson, Alexander" uniqKey="Thompson A" first="Alexander" last="Thompson">Alexander Thompson</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Revill, Peter A" sort="Revill, Peter A" uniqKey="Revill P" first="Peter A" last="Revill">Peter A. Revill</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27534671</idno><idno type="pmid">27534671</idno><idno type="doi">10.1136/gutjnl-2015-309300</idno><idno type="wicri:Area/PubMed/Corpus">000224</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000224</idno><idno type="wicri:Area/PubMed/Curation">000224</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000224</idno><idno type="wicri:Area/PubMed/Checkpoint">000224</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000224</idno><idno type="wicri:Area/Ncbi/Merge">003A05</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.</title><author><name sortKey="Bayliss, Julianne" sort="Bayliss, Julianne" uniqKey="Bayliss J" first="Julianne" last="Bayliss">Julianne Bayliss</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Yuen, Lilly" sort="Yuen, Lilly" uniqKey="Yuen L" first="Lilly" last="Yuen">Lilly Yuen</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Rosenberg, Gillian" sort="Rosenberg, Gillian" uniqKey="Rosenberg G" first="Gillian" last="Rosenberg">Gillian Rosenberg</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Wong, Darren" sort="Wong, Darren" uniqKey="Wong D" first="Darren" last="Wong">Darren Wong</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Littlejohn, Margaret" sort="Littlejohn, Margaret" uniqKey="Littlejohn M" first="Margaret" last="Littlejohn">Margaret Littlejohn</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Jackson, Kathleen" sort="Jackson, Kathleen" uniqKey="Jackson K" first="Kathleen" last="Jackson">Kathleen Jackson</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Gaggar, Anuj" sort="Gaggar, Anuj" uniqKey="Gaggar A" first="Anuj" last="Gaggar">Anuj Gaggar</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Foster City, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Kitrinos, Kathryn M" sort="Kitrinos, Kathryn M" uniqKey="Kitrinos K" first="Kathryn M" last="Kitrinos">Kathryn M. Kitrinos</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Foster City, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Subramanian, G Mani" sort="Subramanian, G Mani" uniqKey="Subramanian G" first="G Mani" last="Subramanian">G Mani Subramanian</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Foster City, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Marcellin, Patrick" sort="Marcellin, Patrick" uniqKey="Marcellin P" first="Patrick" last="Marcellin">Patrick Marcellin</name><affiliation wicri:level="1"><nlm:affiliation>Hôpital Beaujon, University of Paris, Clichy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Beaujon, University of Paris, Clichy</wicri:regionArea><wicri:noRegion>Clichy</wicri:noRegion><wicri:noRegion>Clichy</wicri:noRegion></affiliation></author><author><name sortKey="Buti, Maria" sort="Buti, Maria" uniqKey="Buti M" first="Maria" last="Buti">Maria Buti</name><affiliation wicri:level="3"><nlm:affiliation>Liver Unit, Valle d'Hebron (Ciberehd) University Hospital, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Liver Unit, Valle d'Hebron (Ciberehd) University Hospital, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Janssen, Harry L A" sort="Janssen, Harry L A" uniqKey="Janssen H" first="Harry L A" last="Janssen">Harry L A. Janssen</name><affiliation wicri:level="1"><nlm:affiliation>Toronto Center for Liver Diseases, Toronto Western and General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Center for Liver Diseases, Toronto Western and General Hospital, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Gane, Ed" sort="Gane, Ed" uniqKey="Gane E" first="Ed" last="Gane">Ed Gane</name><affiliation wicri:level="1"><nlm:affiliation>New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Sozzi, Vitina" sort="Sozzi, Vitina" uniqKey="Sozzi V" first="Vitina" last="Sozzi">Vitina Sozzi</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Colledge, Danni" sort="Colledge, Danni" uniqKey="Colledge D" first="Danni" last="Colledge">Danni Colledge</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Hammond, Rachel" sort="Hammond, Rachel" uniqKey="Hammond R" first="Rachel" last="Hammond">Rachel Hammond</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Edwards, Rosalind" sort="Edwards, Rosalind" uniqKey="Edwards R" first="Rosalind" last="Edwards">Rosalind Edwards</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Locarnini, Stephen" sort="Locarnini, Stephen" uniqKey="Locarnini S" first="Stephen" last="Locarnini">Stephen Locarnini</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Thompson, Alexander" sort="Thompson, Alexander" uniqKey="Thompson A" first="Alexander" last="Thompson">Alexander Thompson</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Revill, Peter A" sort="Revill, Peter A" uniqKey="Revill P" first="Peter A" last="Revill">Peter A. Revill</name><affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author></analytic><series><title level="j">Gut</title><idno type="eISSN">1468-3288</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antiviral Agents (therapeutic use)</term><term>Biomarkers (blood)</term><term>DNA, Viral (analysis)</term><term>Double-Blind Method</term><term>Female</term><term>Hepatitis B Surface Antigens (blood)</term><term>Hepatitis B e Antigens (blood)</term><term>Hepatitis B virus (genetics)</term><term>Hepatitis B virus (immunology)</term><term>Hepatitis B, Chronic (blood)</term><term>Hepatitis B, Chronic (drug therapy)</term><term>Hepatitis B, Chronic (virology)</term><term>High-Throughput Nucleotide Sequencing</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Promoter Regions, Genetic</term><term>Sequence Analysis, DNA</term><term>Seroconversion</term><term>Tenofovir (therapeutic use)</term><term>Treatment Outcome</term><term>Viral Load</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ADN viral (analyse)</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de séquence d'ADN</term><term>Antigènes de surface du virus de l'hépatite B (sang)</term><term>Antigènes e du virus de l'hépatite virale B (sang)</term><term>Antiviraux (usage thérapeutique)</term><term>Charge virale</term><term>Femelle</term><term>Humains</term><term>Hépatite B chronique (sang)</term><term>Hépatite B chronique (traitement médicamenteux)</term><term>Hépatite B chronique (virologie)</term><term>Marqueurs biologiques (sang)</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Régions promotrices (génétique)</term><term>Résultat thérapeutique</term><term>Séquençage nucléotidique à haut débit</term><term>Séroconversion</term><term>Ténofovir (usage thérapeutique)</term><term>Virus de l'hépatite B (génétique)</term><term>Virus de l'hépatite B (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>DNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term><term>Hepatitis B Surface Antigens</term><term>Hepatitis B e Antigens</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Tenofovir</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>ADN viral</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Hepatitis B, Chronic</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis B, Chronic</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Virus de l'hépatite B</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Virus de l'hépatite B</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Antigènes de surface du virus de l'hépatite B</term><term>Antigènes e du virus de l'hépatite virale B</term><term>Hépatite B chronique</term><term>Marqueurs biologiques</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hépatite B chronique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Ténofovir</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Hépatite B chronique</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Hepatitis B, Chronic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Double-Blind Method</term><term>Female</term><term>High-Throughput Nucleotide Sequencing</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Promoter Regions, Genetic</term><term>Sequence Analysis, DNA</term><term>Seroconversion</term><term>Treatment Outcome</term><term>Viral Load</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de séquence d'ADN</term><term>Charge virale</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Régions promotrices (génétique)</term><term>Résultat thérapeutique</term><term>Séquençage nucléotidique à haut débit</term><term>Séroconversion</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Hepatitis B e antigen (HBeAg) seroconversion and hepatitis B surface antigen (HBsAg) loss are important clinical outcomes for patients with chronic hepatitis B (CHB) treated with antiviral therapy. To date, there have been few studies that have evaluated viral sequence markers predicting serological response to nucleos(t)ide analogue (NA) treatment.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27534671</PMID><DateCreated><Year>2016</Year><Month>08</Month><Day>18</Day></DateCreated><DateCompleted><Year>2017</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2017</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-3288</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>11</Issue><PubDate><Year>2017</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Gut</Title><ISOAbbreviation>Gut</ISOAbbreviation></Journal><ArticleTitle>Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.</ArticleTitle><Pagination><MedlinePgn>2013-2023</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/gutjnl-2015-309300</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Hepatitis B e antigen (HBeAg) seroconversion and hepatitis B surface antigen (HBsAg) loss are important clinical outcomes for patients with chronic hepatitis B (CHB) treated with antiviral therapy. To date, there have been few studies that have evaluated viral sequence markers predicting serological response to nucleos(t)ide analogue (NA) treatment.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We used next-generation sequencing (NGS) and quantitative HBV serology (HBeAg and HBsAg) to identify viral sequence markers associated with serological response to long-term tenofovir disoproxil fumarate therapy among HBeAg-positive patients. In the GS-US-174-0103 study, approximately half the patients seroconverted to anti-HBe by week 192 and 11% of patients exhibited HBsAg loss, the closest outcome to functional cure. The frequency of HBV variants that have previously been associated with HBV clinical outcomes was evaluated. HBV viral diversity in baseline sequences generated by NGS was calculated using Shannon entropy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">NGS analysis of HBV sequences from 157 patients infected with genotypes A to D showed the frequency of variants in the basal core promoter (BCP) and precore (PC) regions varied by genotype and that these mutations were associated with the absence of HBsAg loss. This was the case even when mutations were present at frequencies below the threshold of detection by population sequencing. Increased viral diversity across the HBV genome as determined by NGS was also associated with reduced likelihood of HBsAg loss.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients with detectable BCP and/or PC variants and higher viral diversity have a lower probability of HBsAg loss during long-term NA therapy. Strategies to achieve functional cure of HBV infection through combination therapy should consider using NGS to stratify patients according to BCP/PC sequence. Consideration should also be given to earlier initiation of therapy prior to the emergence of BCP/PC variants.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">NCT00116805; Post result.</AbstractText><CopyrightInformation>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bayliss</LastName><ForeName>Julianne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuen</LastName><ForeName>Lilly</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Gillian</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Darren</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Littlejohn</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaggar</LastName><ForeName>Anuj</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitrinos</LastName><ForeName>Kathryn M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramanian</LastName><ForeName>G Mani</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcellin</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hôpital Beaujon, University of Paris, Clichy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buti</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Liver Unit, Valle d'Hebron (Ciberehd) University Hospital, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janssen</LastName><ForeName>Harry L A</ForeName><Initials>HLA</Initials><AffiliationInfo><Affiliation>Toronto Center for Liver Diseases, Toronto Western and General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gane</LastName><ForeName>Ed</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sozzi</LastName><ForeName>Vitina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colledge</LastName><ForeName>Danni</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammond</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Rosalind</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Locarnini</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revill</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Division of Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Gut</MedlineTA><NlmUniqueID>2985108R</NlmUniqueID><ISSNLinking>0017-5749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006514">Hepatitis B Surface Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006513">Hepatitis B e Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>99YXE507IL</RegistryNumber><NameOfSubstance UI="D000068698">Tenofovir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004279" MajorTopicYN="N">DNA, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006514" MajorTopicYN="N">Hepatitis B Surface Antigens</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006513" MajorTopicYN="N">Hepatitis B e Antigens</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006515" MajorTopicYN="N">Hepatitis B virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019694" MajorTopicYN="N">Hepatitis B, Chronic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="Y">Promoter Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069078" MajorTopicYN="Y">Seroconversion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068698" MajorTopicYN="N">Tenofovir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CHRONIC VIRAL HEPATITIS</Keyword><Keyword MajorTopicYN="N">HEPATITIS B</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>02</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>07</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>07</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27534671</ArticleId><ArticleId IdType="pii">gutjnl-2015-309300</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2015-309300</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>Canada</li><li>Espagne</li><li>France</li><li>Nouvelle-Zélande</li><li>États-Unis</li></country><region><li>Californie</li><li>Catalogne</li></region><settlement><li>Barcelone</li></settlement></list><tree><country name="Australie"><noRegion><name sortKey="Bayliss, Julianne" sort="Bayliss, Julianne" uniqKey="Bayliss J" first="Julianne" last="Bayliss">Julianne Bayliss</name></noRegion><name sortKey="Colledge, Danni" sort="Colledge, Danni" uniqKey="Colledge D" first="Danni" last="Colledge">Danni Colledge</name><name sortKey="Edwards, Rosalind" sort="Edwards, Rosalind" uniqKey="Edwards R" first="Rosalind" last="Edwards">Rosalind Edwards</name><name sortKey="Hammond, Rachel" sort="Hammond, Rachel" uniqKey="Hammond R" first="Rachel" last="Hammond">Rachel Hammond</name><name sortKey="Jackson, Kathleen" sort="Jackson, Kathleen" uniqKey="Jackson K" first="Kathleen" last="Jackson">Kathleen Jackson</name><name sortKey="Littlejohn, Margaret" sort="Littlejohn, Margaret" uniqKey="Littlejohn M" first="Margaret" last="Littlejohn">Margaret Littlejohn</name><name sortKey="Locarnini, Stephen" sort="Locarnini, Stephen" uniqKey="Locarnini S" first="Stephen" last="Locarnini">Stephen Locarnini</name><name sortKey="Revill, Peter A" sort="Revill, Peter A" uniqKey="Revill P" first="Peter A" last="Revill">Peter A. Revill</name><name sortKey="Rosenberg, Gillian" sort="Rosenberg, Gillian" uniqKey="Rosenberg G" first="Gillian" last="Rosenberg">Gillian Rosenberg</name><name sortKey="Sozzi, Vitina" sort="Sozzi, Vitina" uniqKey="Sozzi V" first="Vitina" last="Sozzi">Vitina Sozzi</name><name sortKey="Thompson, Alexander" sort="Thompson, Alexander" uniqKey="Thompson A" first="Alexander" last="Thompson">Alexander Thompson</name><name sortKey="Wong, Darren" sort="Wong, Darren" uniqKey="Wong D" first="Darren" last="Wong">Darren Wong</name><name sortKey="Yuen, Lilly" sort="Yuen, Lilly" uniqKey="Yuen L" first="Lilly" last="Yuen">Lilly Yuen</name></country><country name="États-Unis"><region name="Californie"><name sortKey="Gaggar, Anuj" sort="Gaggar, Anuj" uniqKey="Gaggar A" first="Anuj" last="Gaggar">Anuj Gaggar</name></region><name sortKey="Kitrinos, Kathryn M" sort="Kitrinos, Kathryn M" uniqKey="Kitrinos K" first="Kathryn M" last="Kitrinos">Kathryn M. Kitrinos</name><name sortKey="Subramanian, G Mani" sort="Subramanian, G Mani" uniqKey="Subramanian G" first="G Mani" last="Subramanian">G Mani Subramanian</name></country><country name="France"><noRegion><name sortKey="Marcellin, Patrick" sort="Marcellin, Patrick" uniqKey="Marcellin P" first="Patrick" last="Marcellin">Patrick Marcellin</name></noRegion></country><country name="Espagne"><region name="Catalogne"><name sortKey="Buti, Maria" sort="Buti, Maria" uniqKey="Buti M" first="Maria" last="Buti">Maria Buti</name></region></country><country name="Canada"><noRegion><name sortKey="Janssen, Harry L A" sort="Janssen, Harry L A" uniqKey="Janssen H" first="Harry L A" last="Janssen">Harry L A. Janssen</name></noRegion></country><country name="Nouvelle-Zélande"><noRegion><name sortKey="Gane, Ed" sort="Gane, Ed" uniqKey="Gane E" first="Ed" last="Gane">Ed Gane</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A05 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003A05 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:27534671
|texte= Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27534671" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |